HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Activation of neurotensin receptor type 1 attenuates locomotor activity.

Abstract
Intracerebroventricular administration of neurotensin (NT) suppresses locomotor activity. However, the brain regions that mediate the locomotor depressant effect of NT and receptor subtype-specific mechanisms involved are unclear. Using a brain-penetrating, selective NT receptor type 1 (NTS1) agonist PD149163, we investigated the effect of systemic and brain region-specific NTS1 activation on locomotor activity. Systemic administration of PD149163 attenuated the locomotor activity of C57BL/6J mice both in a novel environment and in their homecage. However, mice developed tolerance to the hypolocomotor effect of PD149163 (0.1 mg/kg, i.p.). Since NTS1 is known to modulate dopaminergic signaling, we examined whether PD149163 blocks dopamine receptor-mediated hyperactivity. Pretreatment with PD149163 (0.1 or 0.05 mg/kg, i.p.) inhibited D2R agonist bromocriptine (8 mg/kg, i.p.)-mediated hyperactivity. D1R agonist SKF-81297 (8 mg/kg, i.p.)-induced hyperlocomotion was only inhibited by 0.1 mg/kg of PD149163. Since the nucleus accumbens (NAc) and medial prefrontal cortex (mPFC) have been implicated in the behavioral effects of NT, we examined whether microinjection of PD149163 into these regions reduces locomotion. Microinjection of PD149163 (2 pmol) into the NAc, but not the mPFC suppressed locomotor activity. In summary, our results indicate that systemic and intra-NAc activation of NTS1 is sufficient to reduce locomotion and NTS1 activation inhibits D2R-mediated hyperactivity. Our study will be helpful to identify pharmacological factors and a possible therapeutic window for NTS1-targeted therapies for movement disorders.
AuthorsChelsea A Vadnie, David J Hinton, Sun Choi, YuBin Choi, Christina L Ruby, Alfredo Oliveros, Miguel L Prieto, Jun Hyun Park, Doo-Sup Choi
JournalNeuropharmacology (Neuropharmacology) Vol. 85 Pg. 482-92 (Oct 2014) ISSN: 1873-7064 [Electronic] England
PMID24929110 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2014 Elsevier Ltd. All rights reserved.
Chemical References
  • Benzazepines
  • Central Nervous System Agents
  • Dopamine Agonists
  • PD 149163
  • Receptors, Dopamine
  • Receptors, Neurotensin
  • neurotensin type 1 receptor
  • Neurotensin
  • Bromocriptine
  • SK&F 81297
Topics
  • Animals
  • Benzazepines (pharmacology)
  • Bromocriptine (pharmacology)
  • Central Nervous System Agents (pharmacology)
  • Dopamine Agonists (pharmacology)
  • Dose-Response Relationship, Drug
  • Drug Tolerance
  • Environment
  • Housing, Animal
  • Male
  • Mice, Inbred C57BL
  • Microinjections
  • Motor Activity (drug effects, physiology)
  • Muscle Strength (drug effects, physiology)
  • Neurotensin (analogs & derivatives, pharmacology)
  • Nucleus Accumbens (drug effects, physiology)
  • Prefrontal Cortex (drug effects, physiology)
  • Random Allocation
  • Receptors, Dopamine (metabolism)
  • Receptors, Neurotensin (agonists, metabolism)
  • Rotarod Performance Test

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: